Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 22, 2010, Pages 10256-10261

  Wolk, David A ^a,b   Dickerson, Bradford C ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cognition; Cortical thickness; Dementia; Medial temporal lobe; Neuroimaging

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN ATROPHY; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY CONSOLIDATION; NEUROIMAGING; PHENOTYPE; PRIORITY JOURNAL; PSYCHOMETRY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ATROPHY; ATTENTION; CEREBRAL CORTEX; EXECUTIVE FUNCTION; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MEMORY DISORDERS; NERVE NET;

EID: 77953431148     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001412107     Document Type: Article

References (60)

1. McKhann G, et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944. (Pubitemid 14076461)
2. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259.
3. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1:103-116.
4. Dubois B, et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734-746. (Pubitemid 47058377)
5. Johnson JK, Head E, Kim R, Starr A, Cotman CW (1999) Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 56:1233-1239. (Pubitemid 29473215)
6. Hof PR, Bouras C, Constantinidis J, Morrison JH (1989) Balint's syndrome in Alzheimer's disease: Specific disruption of the occipito-parietal visual pathway. Brain Res 493:368-375. (Pubitemid 19183155)
7. Alladi S, et al. (2007) Focal cortical presentations of Alzheimer's disease. Brain 130: 2636-2645. (Pubitemid 47511719)
8. Kanne SM, Balota DA, Storandt M, McKeel DW, Jr, Morris JC (1998) Relating anatomy to function in Alzheimer's disease: Neuropsychological profiles predict regional neuropathology 5 years later. Neurology 50:979-985. (Pubitemid 28212825)
9. Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer's disease. Cortex 44:185-195. (Pubitemid 351729233)
10. Mesulam M (2008) Primary progressive aphasia pathology. Ann Neurol 63:124-125.
11. Strittmatter WJ, et al. (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977-1981.
12. Poirier J, et al. (1993) Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342:697-699.
13. Mahley RW (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240:622-630.
14. Holtzman DM, et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97:2892-2897.
15. Strittmatter WJ, et al. (1994) Hypothesis: Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 125:163-171. (Pubitemid 24076094)
16. Polvikoski T, et al. (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333:1242-1247.
17. Hashimoto M, et al. (2001) Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 57:1461-1466. (Pubitemid 32995729)
18. Pievani M, et al. (2009) Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 45:1090-1098.
19. Geroldi C, et al. (1999) APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 53:1825-1832. (Pubitemid 29530361)
20. Agosta F, et al. (2009) Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci USA 106:2018-2022.
21. Lehtovirta M, et al. (1995) Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 67: 65-72.
22. Jack CR, Jr, et al. (1998) Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 43:303-310.
23. Drzezga A, et al. (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72:1487-1494.
24. Marra C, et al. (2004) Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement Geriatr Cogn Disord 18:125-131.
25. van der Vlies AE, et al. (2007) Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord 24:98-103.
26. Lehtovirta M, et al. (1996) Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism. Neurology 46:413-419.
27. Smith GE, et al. (1998) Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50: 355-362.
28. Varma AR, et al. (1999) Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 66:184-188.
29. Klunk WE, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319.
30. Shaw LM, et al.; Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65:403-413.
31. Dickerson BC, et al. (2009) The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19:497-510.
32. Vincent JL, Kahn I, Snyder AZ, Raichle ME, Buckner RL (2008) Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. J Neurophysiol 100:3328-3342.
33. Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ, Sr, Soininen H (1998) Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele. J Neurol Neurosurg Psychiatry 65: 322-327.
34. Corbetta M, Shulman GL (2002) Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci 3:201-215.
35. Filippini N, et al. (2009) Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease. Neuroimage 44: 724-728.
36. Bakkour A, Morris JC, Dickerson BC (2009) The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology 72:1048-1055.
37. Weintraub S, Mesulam M (2009) With or without FUS, it is the anatomy that dictates the dementia phenotype. Brain 132:2906-2908.
38. Alexander MP, Stuss DT, Fansabedian N (2003) California Verbal Learning Test: Performance by patients with focal frontal and non-frontal lesions. Brain 126: 1493-1503.
39. Miller E (1973) Short- and long-term memory in patients with presenile dementia (Alzheimer's disease). Psychol Med 3:221-224.
40. Becker JT, Bajulaiye O, Smith C (1992) Longitudinal analysis of a two-component model of the memory deficit in Alzheimer's disease. Psychol Med 22:437-445.
41. Baddeley A, Della Sala S, Spinnler H (1991) The two-component hypothesis of memory deficit in Alzheimer's disease. J Clin Exp Neuropsychol 13:372-380.
42. Stopford CL, Snowden JS, Thompson JC, Neary D (2007) Distinct memory profiles in Alzheimer's disease. Cortex 43:846-857.
43. Shallice T, Warrington EK (1970) Independent functioning of verbal memory stores: A neuropsychological study. Q J Exp Psychol 22:261-273.
44. Markowitsch HJ, et al. (1999) Short-term memory deficit after focal parietal damage. J Clin Exp Neuropsychol 21:784-797.
45. Buchsbaum BR, D'Esposito M (2008) The search for the phonological store: from loop to convolution. J Cogn Neurosci 20:762-778.
46. Dickerson BC, et al. (2008) Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths. Neuroimage 39:10-18.
47. Dickerson BC, et al. (2009) Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging 30: 432-440.
48. Feczko E, Augustinack JC, Fischl B, Dickerson BC (2009) An MRI-based method for measuring volume, thickness and surface area of entorhinal, perirhinal, and posterior parahippocampal cortex. Neurobiol Aging 30:420-431.
49. Winkler AM, et al. (2009) Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage, 10.1016/j.neuroimage.2009.12.028.
50. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103:5644-5651.
51. Harris FM, et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100:10966-10971.
52. Scarmeas N, et al. (2005) APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry 76:1440-1444.
53. Brecht WJ, et al. (2004) Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24: 2527-2534.
54. Beffert U, et al. (1999) Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 843:87-94.
55. Acevedo SF, Piper BJ, Craytor MJ, Benice TS, Raber J (2010) Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children. Pediatr Res 67:293-299.
56. Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ (2000) Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. Neurosci Lett 294:179-181.
57. Shaw P, et al. (2007) Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. Lancet Neurol 6: 494-500. (Pubitemid 46734757)
58. Marchant NL, King SL, Tabet N, Rusted JM (2010) Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. Neuropsychopharmacology 35: 1090-1096.
59. Dickerson BC (2007) The entorhinal cortex: An anatomical mediator of genetic vulnerability to Alzheimer's disease? Lancet Neurol 6:471-473.
60. Snodgrass JG, Corwin J (1988) Pragmatics of measuring recognition memory: Applications to dementia and amnesia. J Exp Psychol Gen 117:34-50.